Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLE-2: Buparlisib + Fulvestrant in HR+/HER2- Advanced Breast Cancer
NCT01610284Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2012
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 29
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing BKM120 + Fulvestrant with Placebo + Fulvestrant (2 arms). Primary endpoint: Progression Free Survival at 4 years. Started Aug 2012; status: completed.
02
Drugs
buparlisib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT01610284.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01610284.